MINI FUTURE LONG - NOVO-NORDISK B | Market Closed - Euronext Paris 09:37:48 01/07/2024 pm IST | ||
| 6.505 EUR | +1.09% |
|
| 1 month | +20.51% | ||
| 3 months | +31.73% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 01/24/01 | 6.505 | +1.09% |
| 28/24/28 | 6.435 | +1.42% |
| 27/24/27 | 6.345 | -1.55% |
| 26/24/26 | 6.445 | -3.59% |
| 25/24/25 | 6.685 | +7.91% |
Real-time Euronext Paris
Last update July 01, 2024 at 09:37 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| 0CGMB | |
| ISIN | FRBNPP060XX0 |
| Date issued | 18/09/2023 |
| Strike | 529.4 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.39 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.775 € |
|---|---|
| Lowest since issue | 1.545 € |
| Spread | 0.13 € |
| Spread % | 1.98% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006
DKK
Average target price
949.7
DKK
Spread / Average Target
-5.56%
- Stock Market
- Certificates
- 0CGMB Certificat
